Women’s Infertility - Market Forecasts to 2017 Now Available at SandlerResearch

Dallas, TX -- (SBWire) -- 11/24/2010 -- SandlerResearch announce Women’s Infertility - Pipeline Assessment and Market Forecasts to 2017

Market Forecasts to 2017”. The report is an essential source of information and analysis on the global women’s infertility therapeutics market. The report identifies the key trends shaping and driving the global women’s infertility therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global women’s infertility sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global women’s infertility market was valued at $1,417m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to reach $1,609m by 2017. The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015. Some key branded products, such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon, are going to face a severe threat from generics as they approach patent expiry between 2010 and 2015

Scope
The scope of the report includes:

Annualized global women’s infertility therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Gonadotropin-Releasing hormone (GnRH) antagonists, AMP-activated protein kinase (AMPK) agonists, GnRH agonists, Recombinant human chorionic gonatropin, Follicle stimulating hormone, Selective Estrogen Receptor Modulators (SERMs) and aromatase inhibitor.
Analysis of the current and future market competition in the global women’s infertility therapeutics market. The key future market players covered are Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA and Merck.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the women’s infertility market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global women’s infertility therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global women’s infertility therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

What’s the next big thing in the global women’s infertility therapeutics market landscape? Identify, understand and capitalize.

1 Table of Contents

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Women’s Infertility: Introduction 4
2.1 GlobalData Pipeline Report Guidance 4

3 Women’s Infertility: Market Characterization 5
3.1 Women’s Infertility Market Size 5
3.2 Women’s Infertility Therapeutics Market Forecast and CAGR 6
3.3 Drivers and Barriers for the Women’s Infertility Therapeutics Market 7
3.3.1 Drivers for the Women’s Infertility therapeutics market 7
3.3.2 Barriers for the Women’s Infertility therapeutics market 7
3.4 Opportunity and Unmet Need 7
3.5 Key Takeaway 8

4 Women’s Infertility: Competitive Assessment 9
4.1 Overview 9
4.2 Strategic Competitor Assessment 9
4.3 Major Marketed Products for Women’s Infertility 10
4.3.1 Clomid (clomiphene citrate) 10
4.3.2 Ovidrel (Choriogonadotropin Alfa) 10
4.3.3 GONAL-f (follitropin alfa) 11
4.3.4 Cetrotide (cetrorelix acetate) 12
4.4 Comparison of Major Marketed Products for Women’s Infertility 14
4.5 Key Takeaway 14

5 Women’s Infertility: Pipeline Assessment 15
5.1 Overview 15
5.2 Strategic Pipeline Assessment 15
5.2.1 Technology Trends Analytic Framework 15
5.3 Women’s Infertility Therapeutics – Promising Drugs under Clinical Development 17
5.4 Molecule Profile for Promising Drugs under Clinical Development 17
5.4.1 ELONVA (corifollitropin alfa injection) 17
5.5 Women’s Infertility Therapeutics – Clinical Pipeline by Mechanism of Action 18
5.6 Women’s Infertility Therapeutics – Pipeline by Clinical Phases of Development 19
5.6.1 Women’s Infertility Therapeutics – Phase III Clinical Pipeline 19
5.6.2 Women’s Infertility Therapeutics – Phase II Clinical Pipeline 20
5.6.3 Women’s Infertility Therapeutics – Phase I Clinical Pipeline 20
5.6.4 Women’s Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline 20
5.7 Key Takeaway 20

6 Women’s Infertility: Implications for Future Market Competition 21

7 Women’s Infertility: Future Players in the Women’s Infertility Market 22
7.1 Introduction 22
7.2 Merck & Co. 22
7.2.1 Company Overview 22
7.2.2 Financial Performance 22
7.2.3 Business Description 23
7.3 Dong-A Pharmaceuticals 24
7.3.1 Company Overview 24
7.4 Ferring Pharmaceuticals 25
7.4.1 Company Overview 25
7.5 PregLem SA 26
7.5.1 Company Overview 26

8 Women’s Infertility: Appendix 27
8.1 Market Definitions 27
8.2 Scope of Pipeline Research 27
8.3 Abbreviations 27
8.4 Research Methodology 28
8.4.1 Coverage 28
8.4.2 Secondary Research 29
8.4.3 Forecasting 29
8.4.4 Primary Research 31
8.4.5 Expert Panel Validation 32
8.5 Contact Us 32
8.6 Disclaimer 32
8.7 Sources 32

ABBREVIATIONS

Browse all : Pharmaceuticals Market
http://www.sandlerresearch.org/market-research/pharmaceuticals/

Browse all : GlobalData Market
http://www.sandlerresearch.org/publishers/globaldata/

Browse all : Newly Published Market Research
http://www.sandlerresearch.org/LatestReport.aspx

Related Reports :

Global market review of automotive roof systems – forecasts to 2017
http://www.sandlerresearch.org/reports/17319-global-market-review-of-automotive-roof-systems-forecasts-to-20.html

European Markets for Women's Health Devices 2009 (15 Countries)
http://www.sandlerresearch.org/reports/25418-european-markets-for-womens-health-devices-2009-15-countries.html

Japanese Market for Women's Health Devices 2009
http://www.sandlerresearch.org/reports/18572-japanese-market-for-womens-health-devices-2009.html

U.S. Market for Women's Health Devices 2009
http://www.sandlerresearch.org/reports/25442-us-market-for-womens-health-devices-2009.html

Global Endoscopes Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
http://www.sandlerresearch.org/reports/25474-global-endoscopes-pipeline-analysis-opportunity-assessment-and-m.html

About Sandler Research
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.

Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.

We also provide 24/7 online and offline support to our customers

Contact:

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org
Blog: http://sandlerresearch.blogspot.com/

Original Source : Women Infertility Market
http://www.sandlerresearch.org/reports/32791-womens-infertility-pipeline-assessment-and-market-forecasts-to.html

Buy Now : Market Research
http://www.sandlerresearch.org/reports/15763-major-depressive-disorder-mdd-drug-pipeline-analysis-and-mark.html

Browse complete Report at : Women’s Infertility - Pipeline Assessment and Market Forecasts to 2017
http://www.sandlerresearch.org/reports/32791-womens-infertility-pipeline-assessment-and-market-forecasts-to.html

Media Relations Contact

Ms Sunita
SandlerResearch
888-989-8004
http://www.sandlerresearch.org/

View this press release online at: http://rwire.com/66504